By Robert Preidt
HealthDay Reporter

MONDAY, Aug. 16, 2021 (HealthDay Information) — COVID-19 vaccination triggers a robust immune response in folks with HIV, which means they’re doubtless protected in opposition to the coronavirus, a brand new, small examine exhibits.

“Earlier analysis has prompt a suboptimal response to COVID-19 vaccines in folks living with HIV; nevertheless, these research didn’t totally characterize and outline that response, each for mobile [where the immune system directly attacks infected cells] and humoral [where the immune system circulates virus-fighting antibodies] immunity,” mentioned senior examine creator Dr. Joel Blankson. He’s a professor of medication on the Johns Hopkins College College of Medication, in Baltimore.

“What we discovered with the broadly used Pfizer/BioNTech vaccine was simply the alternative, because it induces strong immune responses in folks residing with HIV, akin to these seen in wholesome folks,” he defined in a Hopkins information launch.

For the examine, Blankson and his colleagues analyzed blood samples collected from seven ladies and 5 males with HIV and from seven ladies and 10 males with out HIV between seven and 17 days after they acquired their second dose of the two-dose Pfizer vaccine.

Not one of the contributors had proof of prior an infection with the coronavirus (SARS-CoV-2) that causes COVID-19.

All the folks with HIV had been on antiretroviral remedy and had a median CD4+ T-cell depend of 913 cells per microliter. Ranges of those immune cells in a wholesome grownup are between 500 to 1,200 cells per microliter, whereas folks with untreated HIV could have counts decrease than 200 cells per microliter.

CD4+ T-cells are additionally referred to as helper T-cells as a result of they help one other sort of immune cell referred to as B-cells in responding to floor proteins (antigens) on viruses corresponding to SARS-CoV-2, the researchers defined.

The researchers additionally checked for the presence and ranges of antibodies in opposition to the protein making up the spikes that protrude from the floor of the coronavirus within the contributors after they’d been totally vaccinated.

“We discovered that there was no important distinction in both the vaccine-produced CD4+ T-cell responses or the titers [levels] of SARS-CoV-2 spike binding antibodies for wholesome contributors and people residing with HIV,” Blankson mentioned. “This means that individuals residing with HIV may be adequately protected in opposition to SARS-CoV-2, with correct vaccination.”

The examine was printed on-line lately within the journal Clinical Infectious Diseases.

Additional analysis is required to find out if folks with HIV who’ve decrease CD4+ T-cell counts get the identical sturdy mobile and humoral immune responses to COVID-19 vaccines because the contributors on this examine, Blankson mentioned.

Extra data

HIV.gov has extra on COVID-19 and people with HIV.

SOURCE: Johns Hopkins Medication, information launch, Aug. 11, 2021